We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Tool Accurately Determines Breast Cancer Prognosis

By LabMedica International staff writers
Posted on 18 Jul 2025

A new study has found that cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to treatment. More...

The research, published in the journal Patterns, marks a significant step toward developing artificial intelligence (AI) tools to help oncologists more accurately determine prognoses and decide which treatments may be most effective on a case-by-case basis.

Researchers at Johns Hopkins University (Baltimore, MD, USA) have designed an interpretable machine learning model that analyzed images of microscopic tissues and biopsy samples from 579 breast cancer patients who were undergoing standard treatments such as chemotherapy. The model examined both the tumor and the surrounding tissue, assessing every cell’s position in relation to the tumor and interactions with neighboring cells. This allowed the algorithm to detect 66 unique cell patterns and categorize patients into seven prognostic groups based on these patterns. Unlike conventional AI methods, the model could clearly identify which specific elements contributed to each pattern, allowing researchers to reverse-engineer the data and uncover the driving factors behind the groupings.

The model’s validation revealed several significant findings. One group of patients with the best survival outcomes had a distinct combination of three cell types: CK8-18high, CXCL12high, and CK+CXCL12+. On the other hand, patients with self-aggregated HER2+ tumor cells had the worst outcomes—a result that aligns with the known aggressiveness of HER2-positive breast cancers. Additionally, triple-negative breast cancer patients with well-organized immune cells surrounding their tumors also had better prognoses than others with the same condition. These results suggest that analyzing spatial tissue patterns may provide oncologists with valuable biomarkers for predicting patient outcomes and personalizing treatment strategies. Moving forward, the researchers plan to expand their methodology to other imaging technologies and apply it to different types of cancer to uncover more actionable insights.

"We're developing a toolbox that you can use anytime you have a massive data set and you don't want to start with an explicit hypothesis," said first author Zhenzhen Wang, a PhD candidate in biomedical engineering at Johns Hopkins University. "Typically, you'd have to design a study to ask if one specific pattern of cells is important, and check if the answer is yes or no. But with our model, we can save time by asking open-ended questions about which patterns are important when trying to understand how patients will respond to treatment or have a better chance of survival."

Related Links:
Johns Hopkins University


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.